Literature DB >> 21299484

Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine.

Scott R Williams1, Paul J Mernagh, Michael H T Lee, Jonathan T Tan.   

Abstract

OBJECTIVE: To evaluate trends in the incidence and serotype profile of invasive pneumococcal disease (IPD) in Australian children under 2 years of age after the introduction of the 7-valent pneumococcal conjugate vaccine (7vPCV). DESIGN AND
SETTING: Analysis of incidence rates calculated using IPD surveillance data (including age, Indigenous status and serotype of the pneumococcal isolate) from 2002 to 2007 obtained from the National Notifiable Diseases Surveillance System and population estimates obtained from the Australian Bureau of Statistics. MAIN OUTCOME MEASURES: Trends in IPD incidence among Indigenous and non-Indigenous children between 2002 and 2007; change in the serotype profile of IPD in non-Indigenous children after the introduction of universal 7vPCV vaccination in 2005.
RESULTS: Overall incidence of IPD decreased by 74% in all children < 2 years of age between 2002 and 2007 (P < 0.001). While the incidence of IPD caused by 7vPCV serotypes decreased significantly among both Indigenous and non-Indigenous children, the incidence of non-7vPCV serotype IPD increased significantly in non-Indigenous children (from 9.7 to 15.7 per 100 000, P < 0.001). Compared with a pre-vaccination period (2002-2004), the 2007 incidence of serotype 19A IPD in non-Indigenous children increased significantly (from 2.7 to 8.6 per 100 000, P < 0.001). In 2007, 19A was the predominant serotype causing IPD (37.7%) in all children aged < 2 years.
CONCLUSIONS: The overall incidence of IPD decreased from 2002 to 2007, primarily driven by a reduction in IPD caused by 7vPCV serotypes. However, this was partially offset by a significant increase in the incidence of IPD caused by non-7vPCV serotypes, particularly 19A, in non-Indigenous children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21299484     DOI: 10.5694/j.1326-5377.2011.tb04192.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  15 in total

1.  Comparative evaluation of the novel IMMUNOCATCHTM Streptococcus pneumoniae (EIKEN CHEMICAL CO., LTD) test with the Uni-GoldTM Streptococcus pneumoniae assay and the BinaxNOW® Streptococcus pneumoniae antigen card for the detection of pneumococcal capsular antigen in urine samples.

Authors:  F Congestrì; M Morotti; R Vicari; M F Pedna; M Sparacino; A Torri; S Bertini; M Fantini; V Sambri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-19       Impact factor: 3.267

2.  Changes in invasive pneumococcal disease serotypes in a regional area of Australia following three years of 7vPCV introduction.

Authors:  Tove Fitzgerald; Peter D Massey; Fakhrul Islam
Journal:  Western Pac Surveill Response J       Date:  2012-06-01

3.  Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

Authors:  Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Rapid urine antigen testing for Streptococcus pneumoniae in adults with community-acquired pneumonia: clinical use and barriers.

Authors:  Aaron M Harris; Susan E Beekmann; Philip M Polgreen; Matthew R Moore
Journal:  Diagn Microbiol Infect Dis       Date:  2014-05-17       Impact factor: 2.803

5.  Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.

Authors:  Laura K Boelsen; Eileen M Dunne; Karen E Lamb; Kathryn Bright; Yin Bun Cheung; Lisi Tikoduadua; Fiona M Russell; E Kim Mulholland; Paul V Licciardi; Catherine Satzke
Journal:  Vaccine       Date:  2015-07-29       Impact factor: 3.641

6.  Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates.

Authors:  S Oftadeh; H F Gidding; G L Gilbert
Journal:  Epidemiol Infect       Date:  2012-09-25       Impact factor: 4.434

7.  Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines.

Authors:  Hyunju Lee; Eun Hwa Choi; Hoan Jong Lee
Journal:  Korean J Pediatr       Date:  2014-02-24

8.  Invasive pneumococcal infection despite 7-valent conjugated vaccine.

Authors:  Sebastien Joye; Anja Gao; Simon Kayemba-Kay's; Jacques Cotting; Marie-Hélène Perez
Journal:  Clin Pract       Date:  2013-03-25

Review 9.  Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.

Authors:  Lucia H Lee; Xin-Xing Gu; Moon H Nahm
Journal:  Vaccines (Basel)       Date:  2014-02-14

10.  Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel.

Authors:  Gili Regev-Yochay; Galia Rahav; Klaris Riesenberg; Yonit Wiener-Well; Jacob Strahilevitz; Michal Stein; Daniel Glikman; Gabriel Weber; Israel Potasman; Ron Dagan
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.